Showing 2421-2430 of 5623 results for "".
- Visus Therapeutics to Host First Capital Markets Day in New York Cityhttps://modernod.com/news/visus-therapeutics-to-host-first-capital-markets-day-in-new-york-city/2479439/Visus Therapeutics announced that the company will host its first Capital Markets Day for investors, analysts, and media on August 31, 2021, from 10 am to 2 pm ET at Convene, 530 Fifth Avenue in New York City. During the Capital Markets Day, members of Visus’ leadership team and leading ey
- Aldeyra Therapeutics Receives Orphan Drug Designation from the FDA for ADX-2191 to Treat Retinitis Pigmentosahttps://modernod.com/news/aldeyra-therapeutics-receives-orphan-drug-designation-from-the-fda-for-adx-2191-to-treat-retinitis-pigmentosa/2479434/Aldeyra Therapeutics announced that the FDA has granted orphan drug designation for ADX-2191 (methotrexate for intravitreal injection) for the treatment of retinitis pigmentosa (RP). Methotrexate inhibits dihydrofolic reductase, an enzyme involved in cellular replication and activation. In
- Oertli’s CataRhex 3 Device Now Equipped With Speep Pump Innovationhttps://modernod.com/news/oertlis-catarhex-3-device-now-equipped-with-speep-pump-innovation/2479420/Oertli Instrumente has expanded the CataRhex 3 to include the pump innovation, “SPEEP,” which is designed to provide more efficiency and precision in cataract surgery due to precise control of flow and vacuum. The CataRhex 3 is Oertli’s compact and portable surgical platf
- EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for Dexycuhttps://modernod.com/news/eyepoint-pharmaceuticals-receives-preliminary-extension-to-pass-through-payment-status-for-dexycu/2479385/EyePoint Pharmaceuticals announced today that the company expects to receive a 9-month extension on Dexycu’s pass-through payment status, which otherwise would expire on March 31, 2022. On July 19, 2021, CMS released its 2022 draft Hospital Outpatient Prospective
- FDA Sets January Deadline to Decide on Full Approval of Pfizer, BioNTech Vaccinehttps://modernod.com/news/fda-sets-january-deadline-to-decide-on-full-approval-of-pfizer-biontech-vaccine/2479380/Pfizer and BioNTech said that the FDA has granted a priority review for an application seeking full approval of their vaccine BNT162b2 to prevent COVID-19 in people 16 years and older, according to a FirstWord
- FDA Grants Alkeus Pharmaceuticals Breakthrough Therapy Designation for ALK-001 for the Treatment of Stargardt Diseasehttps://modernod.com/news/fda-grants-alkeus-pharmaceuticals-breakthrough-therapy-designation-for-alk-001-c20-d3-vitamin-a-for-the-treatment-of-stargardt-disease/2479374/Alkeus Pharmaceuticals announced that the FDA has granted Breakthrough Therapy Designation to ALK-001 for the treatment of Stargardt Disease. ALK-001 (C20-D3-vitamin A) is a chemically-modified form of vitamin A developed to treat multiple retinal degenerati
- First-Of-Its-Kind Visual Prosthesis Brain Implant Developed in Chicago Moves to Clinical Trialhttps://modernod.com/news/first-of-its-kind-visual-prosthesis-brain-implant-developed-in-chicago-moves-to-clinical-trial/2479367/The Intracortical Visual Prosthesis (ICVP) is an implant that connects directly to the brain’s visual cortex, bypassing the retina and optic nerves. The National Institutes of Health has awarded Illinois Tech researchers $2.5 million for the first year of a 3-year project that includes implanting
- Opthea’s OPT-302 Granted FDA Fast Track Designation for Wet AMDhttps://modernod.com/news/optheas-opt-302-granted-fda-fast-track-designation-for-wet-amd/2479360/Opthea has announced FDA has granted Fast Track designation for the company’s VEGF-C/-D ‘trap’ inhibitor, OPT-302, in combination with anti-VEGF-A therapy for the treatment of patients with wet age-related macular degeneration (AMD). The FDA’s Fast Track pro
- Mikajaki Partners With Segula Technologies to Develop Ophthalmic Diagnosis Devicehttps://modernod.com/news/mikajaki-partners-with-segula-technologies-to-develop-ophthalmic-diagnosis-device/2479353/Swiss startup Mikajaki is teaming up with engineering group Segula Technologies to develop the first operational series of EyeLib, an automated diagnostic station that aims to revolutionize the management of the growing number of patients with vision disorders, according to a company news release
- Oasis TEARS PF PLUS Preservative-Free Lubricant Eye Drops Now Delivered in a Bottlehttps://modernod.com/news/oasis-tears-pf-plus-preservative-free-lubricant-eye-drops-now-delivered-in-a-bottle/2479338/Oasis Medical is launching Oasis TEARS PF PLUS preservative-free lubricant eye drops delivered in a 10mL bottle for multiuse. Lubricant eye drops, which are packaged in traditional multi-use bottles, contain preservatives to prevent microbial growth. Preservative-free lubricant eye drops a